Skip to main content

Q&A: Roche responds to the community

Roche has responded to our request by answering questions from the community regarding their recent decision to not initiate any new trials of rugonersen (RO7248824) in Angelman syndrome. 

Questions & Answers from Roche

Please consider joining the ASF/FAST hosted webinar on July 7 at 12pm ET with Dr. Elizabeth Berry-Kravis, a principal investigator for the Roche (Tangelo) program.

Click here to register for the webinar.